. . . . . . . . "Jean-Claude Souvie, Isaac Gonzalez Blanco, Gilles Thominot, Genevieve Chapuis, Stephane Horvath, Gerard Damien, \"Process for the synthesis and crystalline form of agomelatine.\" U.S. Patent US20050182276, issued August 18, 2005."@en . . . . . . . . "138112-76-2"@en . . . . . . . "> 95%"@en . . "# Millan MJ, Brocco M, Gobert A, Dekeyne A: Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl). 2005 Feb;177(4):448-58. Epub 2004 Jul 31. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15289999 # Hardeland R, Poeggeler B, Srinivasan V, Trakht I, Pandi-Perumal SR, Cardinali DP: Melatonergic drugs in clinical practice. Arzneimittelforschung. 2008;58(1):1-10. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18368944 # Racagni G, Riva MA, Popoli M: The interaction between the internal clock and antidepressant efficacy. Int Clin Psychopharmacol. 2007 Oct;22 Suppl 2:S9-S14. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17917564"@en . . . . . . . "approved"@en . . . . . "<2 hours"@en . "investigational"@en . "Agomelatine is indicated for the treatment of major depressive episodes in adults."@en . . . "The novel antidepressant agent, agomelatine, behaves as an agonist at melatonin receptors (MT1 and MT2) and as an antagonist at serotonin (5-HT)(2C) receptors."@en . "Agomelatine"@en . "Agomelatine is structurally closely related to melatonin. Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors, tested in an animal model of depression. Agomelatine was discovered and developed by the European pharmaceutical company Servier Laboratories Ltd. Servier continue to develop the drug and conduct phase III trials in the European Union. In 2005 Servier submitted Agomelatine to the European Medicines Agency (EMEA). On 27 July 2006 the Committee for Medical Products for Human Use (CHMP) of the EMEA recommended a refusal of the marketing authorisation of Valdoxan/Thymanax. The major concern was that efficacy had not been sufficiently shown. In 2006 Servier sold the rights to develop Agomelatine in the US to Novartis. The development for the US market was discontinued in October 2011. It is currently sold in Australia under the Valdoxan trade name."@en . . "Bioavailability is less than 5%."@en . . " "@en . "Valdoxan"@en . . . .